TY - JOUR
T1 - Aspirin, platelet p2y12 receptor inhibitors, and other oral antiplatelets
T2 - Comparative pharmacology and role in elective pci
AU - Kunadian, Vijay
AU - Sinclair, Hannah
AU - Sutton, Aaron
AU - Dangas, George D.
PY - 2013/10
Y1 - 2013/10
N2 - Angina pectoris accounts for a large burden of disease worldwide. Antiplatelet agents play a crucial role in inhibiting the platelet response to vascular injury after percutaneous coronary intervention (PCI) for the management of coronary artery disease. Antiplatelet agents are also essential in the longer term, because the metallic structure of stents is inherently thrombogenic. This article examines the use of aspirin, P2Y12 inhibitors, and other oral antiplatelets in the setting of elective PCI. Dual antiplatelet therapy in elective PCI is now standard therapy. The clinical use of novel antiplatelet therapy in the setting requires further evaluation.
AB - Angina pectoris accounts for a large burden of disease worldwide. Antiplatelet agents play a crucial role in inhibiting the platelet response to vascular injury after percutaneous coronary intervention (PCI) for the management of coronary artery disease. Antiplatelet agents are also essential in the longer term, because the metallic structure of stents is inherently thrombogenic. This article examines the use of aspirin, P2Y12 inhibitors, and other oral antiplatelets in the setting of elective PCI. Dual antiplatelet therapy in elective PCI is now standard therapy. The clinical use of novel antiplatelet therapy in the setting requires further evaluation.
KW - Antiplatelet agents
KW - Elective angioplasty
KW - Percutaneous coronary intervention
UR - http://www.scopus.com/inward/record.url?scp=84884989376&partnerID=8YFLogxK
U2 - 10.1016/j.iccl.2013.05.010
DO - 10.1016/j.iccl.2013.05.010
M3 - Review article
AN - SCOPUS:84884989376
SN - 2211-7458
VL - 2
SP - 527
EP - 535
JO - Interventional Cardiology Clinics
JF - Interventional Cardiology Clinics
IS - 4
ER -